gpc3 and/or tgfβ targeting car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03198546)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming growth factor beta-2Immunity, passive
TGFB2 immunity, passive
- Glypican-3Immunity, passive
immunity, passive - gpc3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03198546 | Phase 1 | Jul 1, 2017 | Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Guangzhou Medical University, Hunan Yongren Medical Innovation Co. Ltd., Sun Yat-Sen University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangdong Zhaotai InVivo Biomedicine Co. Ltd. | Government | 1 | 0 | 1 | 2017 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Hunan Yongren Medical Innovation Co. Ltd. | Government | 1 | 0 | 1 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1